All-trans-retinoic acid-induced growth suppression of blastemal Wilms' tumor

Pediatric Pathology and Laboratory Medicine

Volumn 16, Issue 5, 1996, Pages 777-790

  Vincent, Timothy S ^a   Re, Gian G ^a   Hazen Martin, Debra J ^a   Tarnowski, Betty I ^a   Willingham, Mark C ^a   Julian Garvin, A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

differentiation; insulin like growth factor II; N myc; retinoic acid; Wilms' tumor

Indexed keywords

MESSENGER RNA; RETINOIC ACID; SOMATOMEDIN BINDING PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLASTEMA; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION; HUMAN; HUMAN CELL; NEPHROBLASTOMA; NONHUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0029774352     PISSN: 10771042     EISSN: None     Source Type: Journal    
DOI: 10.1080/107710496175390     Document Type: Article

References (38)

1. Matsunaga E. Genetics of Wilms' tumor. Hum Genet 1981;57:231-46.
2. Haber DA, Housman DE. The genetics of Wilms' tumor. Adv Cancer Res 1992;59:41-68.
3. Coppes MJ, Campbell CE, Williams BRG. The role of WT1 in Wilms tumorigenesis. FASEB J 1993;7:886-95.
4. Rauscher FJ. The WT1 Wilms tumor gene product: A developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J 1993;7:896-903.
5. Goodyer P, Dehbi M, Torban E, Bruening W, Pelletier J. Repression of the retinoic acid receptor-α gene by the Wilms' tumor suppressor gene product, wt1. Oncogene 1995;- 10:1125-9.
6. Reeve AE, Eccles MR, Wilkins RJ, Bell GI, Millow LJ. Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature 1985;317:258-60.
7. Scott J, Cowell J, Robertson ME, et al. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. Nature 1985:317:260-2.
8. Gansler T, Allen KD, Burant CF, et al. Detection of type 1 insulinlike growth factor (IGF) receptors in Wilms' tumors. Am J Pathol 1988;130:431-5.
9. Gansler T, Furlanetto R, Gramling TS, et al. Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice. Am J Pathol 1989;135:961-6.
10. Vincent TS, Garvin AJ, Gramling TS, Hazen-Martin DJ, Re GG, Sens DA. Expression of insulin-like growth factor binding protein 2 (IGFBP-2) in Wilms' tumors. Pediatr Pathol 1994;14:723-30.
11. Sporn MB, Roberts AB, Goodman DS, eds. The Retinoids. 2nd ed. New York: Raven Press, 1994.
12. Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 1981;57:1000-4.
13. Sidell N, Altman A, Haussler MR, Seeger RC. Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res 1983;148:21-30.
14. Crouch CD, Helman LJ. All-trans retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines. Cancer Res 1991;51:4882-7.
15. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:1704-9.
16. Garvin AJ, Sullivan JL, Bennett DD, Stanley WS, Inabnett T, Sens DA. The in vitro growth, hetero-transplantation, and immunohistochemical characterization of the blastemal component of Wilms' tumor. Am J Pathol 1987;129:353-63.
17. Vincent TS, Wülfert E, Merler E. Inhibition of growth factor signaling pathways by lovastatin. Biochem Biophys Res Commun 1991;180:1284-9.
18. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem 1987;162:156-9.
19. Re GG, Estrov Z, Antoun GR, Felix EA, Pinkel DP, Zipf TF. Differentiation in B-precursor acute lymphoblastic leukemia cell populations with CD34-positive subpopulations. Blood 1991;78:575-80.
20. Bell GI, Merryweather JP, Sanchez-Pescador R, et al. Sequence of a cDNA clone encoding human preproinsulin-like growth factor II. Nature 1984;310:775-7.
21. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-20.
22. Dressler GR, Deutsch U, Chowdhury K, Nornes HO, Gruss P. Pax2, a new murine paired-box-containing gene and its expression in the developing excretory system. Development 1990;109:787-95.
23. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. Analysis of serum insulin-like growth factor binding proteins using Western blotting: Use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 1986;154:138-43.
24. Clemmons DR, Jones Jl, Busby WH, Wright G. Role of insulin-like growth factor binding proteins in modifying IGF actions. Ann NY Acad Sci 1993;692:10-21.
25. Martin SJ, Bradley JG, Cotter TG. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol 1990;79:448-53.
26. Atencia R, Garcia-Sanz M, Unda F, Aréchaga J. Apoptosis during retinoic acid-induced differentiation of F9 embryonal carcinoma cells. Exp Cell Res 1994;214:663-7.
27. Ueno T, Suita S, Zaizen Y. Retinoic acid induces insulin-like growth factor II expression in a neuroblastoma cell line. Cancer Lett 1993;71:177-82.
28. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985;313:404-6.
29. Amatruda TT, Sidell N, Ranyard J, Koeffler HP. Retinoic acid treatment of human neuroblastoma cells is associated with decreased N-myc expression. Biochem Biophys Res Commun 1985:126:1189-95.
30. Blackwood EM, Eisenman RN. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991;251:1211-17.
31. Collum RG, Alt FW. Are myc proteins transcription factors? Cancer Cells 1990;2:69-75.
32. Serra R, Pelton RW, Moses HL. TGFß1 inhibits branching morphogenesis and N-myc expression in lung bud organ cultures. Development 1994;120:2153-61.
33. Stanton BR, Perkins AS, Tessarollo L, Sassoon DA, Parada LF. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev 1992;6:2235-47.
34. Charron J, Malynn BA, Fisher P, et al. Embryonic lethality in mice homozygous for a targeted disruption of the N-mycgene. Genes Dev 1992:6:2248-57.
35. Sawai S, Shimono A, Wakamatsu Y, Palmes C, Hanaoka K, Kondoh H. Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse. Development 1993;117:1445-55.
36. Sekiya M, Adachi M, Hinoda Y, Imai K, Yachi A. Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. Blood 1994;83:1876-82.
37. Adamson PC. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer. Leukemia 1994;8:1813-16.
38. Adamson PC, Reaman G, Feusner J, Murphy RF, O'Brien M, Balis FM. Pediatric phase I trial and pharmacokinetic study of all-trans-retinoic (ATRA) acid administered on an intermittent schedule. Prog/Proc Am Soc Clin Oncol 1995:14:363.